<p>This is a summary of the European public assessment report (EPAR) for Amyvid. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Amyvid.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>This medicinal product is for diagnostic use only.</p> <p>Amyvid is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of ?-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Amyvid should be used in conjunction with a clinical evaluation.</p> <p>A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.</p></div>
Therapeutic Area (MeSH)
ATC Code
V09AX05
ATC Item
N/A
Pharmacotherapeutic Group
Diagnostic radiopharmaceuticals
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| florbetapir (18F) | N/A | florbetapir (18F) |
EMA Name
Amyvid
Medicine Name
Amyvid
Aliases
N/ANo risk management plan link.
